CannabisNCT07699198
Developing and Strengthening Cannabis Warnings: Warning Message Testing
A study testing Constituents, Cognitive Functioning and Cardiovascular Health in people with Cannabis and Marijuana Use, run by University of North Carolina, Chapel Hill at 1 site in United States.
Trial summary
The purpose of this activity is to identify promising cannabis warning messages from different themes. Participants will be adults who live in the United States, including both people who use cannabis and those who do not use cannabis. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cannabis, Marijuana Use
- What is being tested?
- Constituents, Cognitive Functioning and Cardiovascular Health
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,750 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jul 2026to 27 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 years of age and older
- Live in the United States
Who cannot join
- Age less than 18 years of age
- Does not live in the United States
Trial locations and contacts
1 site in 1 country.
United States1 site
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514
About this study
The purpose of this activity is to identify promising cannabis warning messages from different themes. Participants will be adults who live in the United States, including both people who use cannabis and those who do not use cannabis. In an online within-subjects experiment, participants will be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. The survey will take 15-20 minutes.
Read the detailed description
The purpose of this activity is to identify promising cannabis warning messages from different themes.
Setting: An online survey of adults who live in the United States.
Participants: An estimated N=1500 adults who live in the United States, including both people who use cannabis and those who do not use cannabis. Participants will be recruited by Qualtrics Services. Participants who are eligible for the study will view a consent form as part of the survey and check a box to indicate that they agree to participate in the study. Once the participant has completed consent, they will be able to begin the survey.
Procedures: Participants will complete a within-subjects experiment in which they view and rate cannabis warning messages from different themes. Participants will be screened for inclusion and answer questions on demographic information and susceptibility to cannabis use. Participants will then be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. There will be a total of 11 warning themes plus control. After viewing and rating their assigned cannabis warning messages, participants will answer additional questions about cannabis risk perceptions and use behavior (if applicable), additional demographic information, and about their use of tobacco and alcohol. The survey will take 15-20 minutes.
- Conditions
- Cannabis, Marijuana Use
- Being tested
- Constituents, Cognitive Functioning, Cardiovascular Health, Motor Vehicle Crashes, Dependence
- Keywords
- Cannabis, Marijuana Use, Product Packaging, Product Labeling, Warnings, Health Communication
- Medical subject headings
- Marijuana Abuse, Marijuana Use
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ConstituentsBehavioural
Participants will view and rate a message about constituents.
Cognitive FunctioningBehavioural
Participants will view and rate a message about cognitive functioning.
Cardiovascular HealthBehavioural
Participants will view and rate a message about cardiovascular health.
Motor Vehicle CrashesBehavioural
Participants will view and rate a message about motor vehicle crashes.
DependenceBehavioural
Participants will view and rate a message about dependence.
Psychosis and SchizophreniaBehavioural
Participants will view and rate a message about psychosis and schizophrenia.
Mental HealthBehavioural
Participants will view and rate a message about mental health.
Reproductive HealthBehavioural
Participants will view and rate a message about reproductive health.
Respiratory HealthBehavioural
Participants will view and rate a message about respiratory health.
EdiblesBehavioural
Participants will view and rate a message about edibles.
Cannabis Hyperemesis SyndromeBehavioural
Participants will view and rate a message about cannabis hyperemesis syndrome.
ControlBehavioural
Participants will view and rate a control message.
| Study group | Role | What they receive |
|---|---|---|
| Cannabis warning messages | Experimental | Participants will view and rate 7 cannabis warning messages. The cannabis warning messages cover 11 different themes plus a control theme and were identified in a previous study activity.
Theme 1: Constituents Theme 2: Cognitive Functioning Theme 3: Cardiovascular Health Theme 4: Motor Vehicle Crashes Theme 5: Dependence Theme 6: Psychosis and Schizophrenia Theme 7: Mental Health Theme 8: Reproductive Health Theme 9: Respiratory Health Theme 10: Edibles Theme 11: Cannabis Hyperemesis Syndrome Theme 12: Control Receives: Behavioral: Constituents; Behavioral: Cognitive Functioning; Behavioral: Cardiovascular Health; Behavioral: Motor Vehicle Crashes; Behavioral: Dependence; Behavioral: Psychosis and Schizophrenia; Behavioral: Mental Health; Behavioral: Reproductive Health; Behavioral: Respiratory Health; Behavioral: Edibles; Behavioral: Cannabis Hyperemesis Syndrome; Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Elaboration
A one item measure of cognitive elaboration to assess how much a message makes the participant think about the health risks of cannabis. Response options are on a 5-point scale from 5='A great deal' to 1= 'Not at all', with higher scores indicating higher cognitive elaboration.
Measured: Baseline (one time online survey)
Secondary outcomes (1)
Perceived Message Effectiveness
This survey item assesses perceived message effectiveness in terms of how concerned the message makes the participant feel about the health effects of using cannabis. Response options are on a 5-point scale from 5='A great deal' to 1='Not at all' with higher scores indicating higher perceived message effectiveness.
Measured: Baseline (one time online survey)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start31 Jul 2026
- Primary completion27 Aug 2026
- Study completion27 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CannabisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,750 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Responsible party
- Sponsor
- Investigators
- Sarah D Kowitt, PhD, MPH, Principal investigator, University of North Carolina, Chapel HillLeah M Ranney, PhD, MA, Principal investigator, University of North Carolina, Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07699198
- Sponsor's protocol ID
- 24-1616
- Other IDs
- R01DA058003
- Status last verified
- Sep 2026
- First submitted
- 25 Jun 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: A de-identified version of individual participant data will be shared through the UNC Dataverse
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing and Strengthening Cannabis Warnings: Warning Message Testing
- ClinicalTrials.gov ID
- NCT07699198
- Acronym / sponsor ID
- 24-1616
- Conditions
- Cannabis, Marijuana Use
- Keywords
- Cannabis, Marijuana Use, Product Packaging, Product Labeling, Warnings, Health Communication
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,750 participants (actual)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Study start
- 31 Jul 2026 (actual)
- Primary completion
- 27 Aug 2026 (actual)
- Study completion
- 27 Aug 2026 (actual)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this activity is to identify promising cannabis warning messages from different themes. Participants will be adults who live in the United States, including both people who use cannabis and those who do not use cannabis. In an online within-subjects experiment, participants will be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. The survey will take 15-20 minutes.
Detailed description
The purpose of this activity is to identify promising cannabis warning messages from different themes.
Setting: An online survey of adults who live in the United States.
Participants: An estimated N=1500 adults who live in the United States, including both people who use cannabis and those who do not use cannabis. Participants will be recruited by Qualtrics Services. Participants who are eligible for the study will view a consent form as part of the survey and check a box to indicate that they agree to participate in the study. Once the participant has completed consent, they will be able to begin the survey.
Procedures: Participants will complete a within-subjects experiment in which they view and rate cannabis warning messages from different themes. Participants will be screened for inclusion and answer questions on demographic information and susceptibility to cannabis use. Participants will then be randomly assigned to view 7 cannabis warning messages from different themes developed as part of previous study activities. After viewing each cannabis warning message, participants will rate the message on awareness, clarity, believability, cognitive elaboration, perceived message effectiveness, and reactance. There will be a total of 11 warning themes plus control. After viewing and rating their assigned cannabis warning messages, participants will answer additional questions about cannabis risk perceptions and use behavior (if applicable), additional demographic information, and about their use of tobacco and alcohol. The survey will take 15-20 minutes.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cannabis warning messages | Experimental | Behavioral: Constituents, Behavioral: Cognitive Functioning, Behavioral: Cardiovascular Health, Behavioral: Motor Vehicle Crashes, Behavioral: Dependence, Behavioral: Psychosis and Schizophrenia, Behavioral: Mental Health, Behavioral: Reproductive Health, Behavioral: Respiratory Health, Behavioral: Edibles, Behavioral: Cannabis Hyperemesis Syndrome, Behavioral: ControlParticipants will view and rate 7 cannabis warning messages. The cannabis warning messages cover 11 different themes plus a control theme and were identified in a previous study activity. Theme 1: Constituents Theme 2: Cognitive Functioning Theme 3: Cardiovascular Health Theme 4: Motor Vehicle Crashes Theme 5: Dependence Theme 6: Psychosis and Schizophrenia Theme 7: Mental Health Theme 8: Reproductive Health Theme 9: Respiratory Health Theme 10: Edibles Theme 11: Cannabis Hyperemesis Syndrome Theme 12: Control |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age 18 years of age and older
- Live in the United States
Key exclusion criteria (2 listed)
- Age less than 18 years of age
- Does not live in the United States
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ConstituentsParticipants will view and rate a message about constituents. | Behavioural | Cannabis warning messages |
| Cognitive FunctioningParticipants will view and rate a message about cognitive functioning. | Behavioural | Cannabis warning messages |
| Cardiovascular HealthParticipants will view and rate a message about cardiovascular health. | Behavioural | Cannabis warning messages |
| Motor Vehicle CrashesParticipants will view and rate a message about motor vehicle crashes. | Behavioural | Cannabis warning messages |
| DependenceParticipants will view and rate a message about dependence. | Behavioural | Cannabis warning messages |
| Psychosis and SchizophreniaParticipants will view and rate a message about psychosis and schizophrenia. | Behavioural | Cannabis warning messages |
| Mental HealthParticipants will view and rate a message about mental health. | Behavioural | Cannabis warning messages |
| Reproductive HealthParticipants will view and rate a message about reproductive health. | Behavioural | Cannabis warning messages |
| Respiratory HealthParticipants will view and rate a message about respiratory health. | Behavioural | Cannabis warning messages |
| EdiblesParticipants will view and rate a message about edibles. | Behavioural | Cannabis warning messages |
| Cannabis Hyperemesis SyndromeParticipants will view and rate a message about cannabis hyperemesis syndrome. | Behavioural | Cannabis warning messages |
| ControlParticipants will view and rate a control message. | Behavioural | Cannabis warning messages |
Primary outcome
Cognitive Elaboration
Time frame: Baseline (one time online survey)
A one item measure of cognitive elaboration to assess how much a message makes the participant think about the health risks of cannabis. Response options are on a 5-point scale from 5='A great deal' to 1= 'Not at all', with higher scores indicating higher cognitive elaboration.
1 secondary outcome
Perceived Message Effectiveness
Time frame: Baseline (one time online survey)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: Yes. A de-identified version of individual participant data will be shared through the UNC Dataverse
Related trials for Cannabis
Active, not recruitingObservational study
Cannabis Use and Outcomes in Black and White Patients With Cancer
Cancer
Recruiting
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
Alcohol Use, Cannabis Use
RecruitingObservational study
A Study in Patients Reporting Cannabis Use Followed With an Application-Based Cannabis Journal
Cancer
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Not yet recruitingEarly Phase 1
Research Investigating Drug Effects-2 (RiDE-2)
Cannabis Use, Substance Use Disorder (SUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah D Kowitt, PhD, MPH principal investigator
University of North Carolina, Chapel Hill
Leah M Ranney, PhD, MA principal investigator
University of North Carolina, Chapel Hill
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Constituents, Cognitive Functioning and Cardiovascular Health in people with Cannabis and Marijuana Use, run by University of North Carolina, Chapel Hill at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Elaboration (time frame: Baseline (one time online survey)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.